article · RSC Advances
This study explored the flavonoid-rich extract of beetroot (<i>Beta vulgaris</i> L.) for type 2 diabetes mellitus (T2D) and Alzheimer's disease (AD) dual therapy by using <i>in vitro</i> and molecular simulation studies. Flavonoid-rich extracts of <i>B. vulgaris</i> fruit were evaluated for their antidiabetic and anti-alzheimic activities. Molecular docking and dynamic simulation were performed to identify potential bioactive flavonoids with dual therapeutic effects on T2D and AD. Flavonoid-rich extracts of <i>B. vulgaris</i> fruit (IC<sub>50</sub> = 73.062 ± 0.480 μg mL<sup>-1</sup>) had moderate activity against α-amylase compared to the standard acarbose (IC<sub>50</sub> = 27.104 ± 0.270 μg mL<sup>-1</sup>). Compared with acarbose, flavonoid-rich extracts of <i>B. vulgaris</i> fruit had appreciable activity against α-glucosidase (IC<sub>50</sub> = 17.389 ± 0.436 μg mL<sup>-1</sup>) (IC<sub>50</sub> = 37.564 ± 0.620 μg mL<sup>-1</sup>). For AChE inhibition, flavonoid-rich extracts of <i>B. vulgaris</i> fruit exhibited (<i>p</i> < 0.0001) inhibitory activity (IC<sub>50</sub> = 723.260 ± 5.466 μg mL<sup>-1</sup>), albeit weaker than that of the standard control, galantamine (IC<sub>50</sub> = 27.950 ± 0.122 μg mL<sup>-1</sup>). Similarly, flavonoid-rich extracts of <i>B. vulgaris</i> fruit showed considerable (<i>p</i> < 0.0001) inhibitory effects on BChE (IC<sub>50</sub> = 649.112 ± 0.683 μg mL<sup>-1</sup>). In contrast, galantamine (IC<sub>50</sub> = 23.126 ± 0.683 μg mL<sup>-1</sup>) is more potent than the extracts of <i>B. vulgaris</i> fruit. Monoamine oxidase (MAO) activity increased in FeSO<sub>4</sub>-induced brain damage. In contrast, flavonoid-rich extracts of <i>B. vulgaris</i> fruit protected against Fe<sup>2+</sup>-mediated brain damage by suppressing MAO activity in a concentration-dependent manner. HPLC-DAD profiling of the extracts identified quercetrin, apigenin, rutin, myricetin, iso-quercetrin, <i>p</i>-coumaric acid, ferulic acid, caffeic acid, and gallic acid. Molecular docking studies revealed quercetrin, apigenin, rutin, iso-queretrin, and myricetin were the top docked bioactive flavonoids against the five top target proteins (α-amylase, α-glucosidase AchE, BchE, and MAO). Molecular dynamic simulations revealed that the complexes formed remained stable over the course of the simulation. Collectively, the findings support the prospect of flavonoid-rich extracts of <i>B. vulgaris</i> root functioning as a dual therapy for T2D and AD.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1039/d4ra03638g
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.